Ruibo (Taizhou) Pharmaceutical Co., Ltd.s announced a placement of common shares for gross proceeds of CNY 600,000,000 on January 20, 2023. The transaction will include participation from returning investor, Zhejiang Jiuzhou Pharmaceutical Co., Ltd. In the transaction, CNY 50,000,000 will go to registered capital, and the company's registered capital will increase from CNY 100,000,000 to CNY 150,000,000. The transaction has been approved in the 26th meeting of Zhejiang Jiuzhou Pharmaceutical Co., Ltd's 7th directorate and the 20th meeting of the 7th supervisory board and does not need the shareholders' approval.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.57 CNY | +1.80% |
|
+4.30% | -43.95% |
05-24 | Tranche Update on Zhejiang Jiuzhou Pharmaceutical Co., Ltd's Equity Buyback Plan announced on January 5, 2024. | CI |
05-23 | Jiuzhou Pharmaceutical Plans CRO in Germany | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-43.95% | 1.65B | |
+55.35% | 848B | |
+31.64% | 627B | |
-0.10% | 363B | |
+15.47% | 318B | |
+13.10% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.54% | 179B | |
+4.31% | 167B |
- Stock Market
- Equities
- 603456 Stock
- News Zhejiang Jiuzhou Pharmaceutical Co., Ltd
- Ruibo Pharmaceutical Co., Ltd. announced that it expects to receive CNY 600 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd